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Review Article
Role of Pelvic Lymphadenectomy in the Treatment of Bladder 
Cancer: A Mini Review
Ja Hyeon Ku
Department of Urology, Seoul National University Hospital, Seoul, Korea
Although radical cystectomy with pelvic lymph node dissection (PLND) is the standard 
treatment for muscle-invasive bladder cancer, the optimal extent of PLND and the mini-
mum number of nodes that should be examined for pathology remain unclear. However, 
evidence is growing that extended PLND has additional diagnostic and therapeutic 
benefits relative to standard PLND. In particular, a more meticulous and extended 
PLND may improve the disease-free survival of node-negative patients because it re-
moves undetected micrometastases. Indeed, some patients with positive nodes can be 
cured by surgery alone, even those with gross adenopathy. Increasing lines of evidence 
also suggest that the extent of the primary bladder tumor, the number of lymph nodes 
that are removed, and the lymph node tumor burden are important prognostic variables 
in patients undergoing cystectomy. Therefore, extended PLND may not only provide 
improved prognostic information, it may also have a clinically significant therapeutic 
benefit for both lymph node-positive and node-negative patients undergoing radical 
cystectomy. Although the absolute limits of PLND remain to be determined, evidence 
supports the notion that a more extended PLND should include the common iliac vessels 
and presacral lymph nodes at cystectomy. Such PLND should only be performed in patients 
who are appropriate surgical candidates. Prospective, randomized trials are needed 
to properly establish the extent of PLND that is required to generate these benefits.
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INTRODUCTION
High-grade muscle-invasive bladder cancer is regarded as 
a potentially lethal disease that has a high propensity for 
spreading. If left untreated, 85% of these patients will die 
from the disease within 2 years of diagnosis [1]. Radical cys-
tectomy with bilateral pelvic lymph node dissection 
(PLND) is the standard treatment for high-grade invasive 
bladder cancer. In 1982, Skinner recognized for the first 
time that PLND could be curative for those bladder cancer 
patients who have only a few small positive lymph nodes 
[2]. He concluded that a meticulous PLND that extends to 
the common iliac vessels and the distal aorta and vena cava 
does not increase the morbidity or mortality associated 
with cystectomy and can make a difference in terms of 
survival. However, despite the accumulating evidence sug-
gesting that a more extensive PLND is an important com-
ponent in the surgical management of bladder cancer, how 
extensive PLND should be and what role it plays in re-
ducing bladder cancer mortality remain unclear.
LYMPHATIC DRAINAGE OF THE BLADDER
The primary drainage of the bladder starts from the ex-
ternal and internal iliac and obturator sites, secondary 
drainage is from the common iliac sites, and tertiary drain-
age to the presacral nodes is from the trigone and posterior 
bladder wall [3]. 
　Standard PLND is currently defined by the following 
boundaries: the common iliac bifurcation (cephalad ex-
tent), the genito-femoral nerve (lateral), the circumflex 
caudal iliac vein and lymph node of Cloquet (distal), and Korean J Urol 2010;51:371-378
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TABLE 1. Incidence of node metastases detected after radical cystectomy
References Year No. of patients No. of node metastases  Node metastases (%)
Ghoneim et al [6]
Poulsen et al [7]
Vieweg et al [8]
Bassi et al [9]
Leissner et al [10]
Herr and Donat [11]
Mills et al [12]
Stein et al [13]
Gschwend et al [14]
Gaitonde et al [15]
Madersbacher et al [16]
Vazina et al [3]
Leissner et al [4]
Abdel-Latif et al [17]
Nishiyama et al [18]
Fleischmann et al [19]
Hautmann et al [20]
Shariat et al [21]
Honma et al [22]
Koppie et al [23]
Stein et al [24]
Steven and Poulsen [25]
Dhar et al [26]
Ghoneim et al [27] 
Wiesner et al [28]
Osawa et al [29]
Jensen et al [30]
Bruins et al [31]
Stephenson et al [32]
Seiler et al [33]
Dangle et al [34]
1997
1998
1999
1999
2000
2001
2001
2001
2002
2002
2003
2004
2004
2004
2004
2005
2006
2006
2006
2006
2007
2007
2008
2008
2009
2009
2009
2009
2010
2010
2010
1,026
191
682
369
447
763
452
1,054
686
105
507
176
290
418
1,113
507
788
833
146
1,110
1,621
336
336
991
152
435
170
1,600
763
840
120
188
50
193
78
136
193 
83
246
193
17
121
43
81
110
162
124
142
198
25
243
383
64
43
233
46
83
43
369
178
162
36
19.5
26.2
28.1
21.1
30.4
25.3
18.4
23.3
28.1
16.2
23.9
24.4
27.9
26.3
14.6
24.5
18.0
23.8
17.1
21.9
23.6
19.0
12.8
23.6
30.2
19.1
25.3
23.1
23.3
19.3
30.0
the hypogastric vessels (posterior), including the obturator 
fossa. The whole primary lymphatic drainage system of the 
bladder is contained within these boundaries. Extended 
PLND should include the nodes contained within the fol-
lowing boundaries: the aortic bifurcation and common iliac 
vessels (proximal/cephalad); the genito-femoral nerve 
(lateral); the circumflex (distal) and caudal iliac vein and 
lymph node of Cloquet; the hypogastric vessels (posterior), 
including the obturator fossa; and the presacral lymph no-
des anterior to the sacral promontory. These boundaries 
potentially guarantee the complete removal of the pri-
mary, secondary, and tertiary lymph node drainage sys-
tems of the bladder, which will aid the accuracy of staging. 
　The group from Mansoura suggested that the endopelvic 
(obturator and internal iliac) lymph nodes could serve as 
lymphatic drainage sentinels; they also speculated that if 
histology of frozen sections of endopelvic nodes revealed that 
the nodes were negative, there was no justification for ex-
tending the PLND superiorly [4,5]. This possibility should 
be confirmed by larger studies.
INCIDENCE OF NODE INVOLVEMENT 
FOLLOWING RADICAL CYSTECTOMY 
The reported incidence of regional lymph node involve-
ment following radical cystectomy for bladder cancer is be-
tween 13% and 30% (Table 1) [3,4,6-34]. This incidence cor-
relates positively with the stage of the primary tumor: the 
higher the stage, the greater the incidence of node involve-
ment [10,12]. The rate of lymph node metastasis increases 
from 5% in non-muscle-invasive bladder cancer to 18% in 
superficial muscle-invasive cancer, 27% in deep-muscle- 
invasive cancer, and 45% in extravesical cancer (pT3-4) 
[13]. In addition, Herr reported that the number of patients 
with positive nodes increases with the number of lymph no-
des that are removed [35]. Table 1 summarizes the in-
cidence of node metastases in patients treated by radical 
cystectomy. 
ASSOCIATION BETWEEN LYMPH NODE 
DISSECTION AND THE NUMBER OF RETRIEVED 
NODES 
The absolute boundaries of the PLND may be the most im-Korean J Urol 2010;51:371-378
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TABLE 2. Extent of pelvic lymph node dissection and the number of retrieved nodes
References Year No. of patients Extent No. of nodes
Poulsen et al [7] 1998 72
45
Aortic bifurcation
Common iliac bifurcation
25.0
14.0
Leissner et al [10] 2000 302 Common iliac bifurcation 14.6
Mills et al [12] 2001 452 Common iliac bifurcation 20.0
Herr [35] 2003 162 Distal common iliac 13.3
Stein et al [37] 2003 244 2 cm above aortic bifurcation 30.0
Vazina et al [3] 2004 176 Aortic bifurcation 26.0
Leissner et al [4] 2004 290 Above aortic bifurcation 43.1
Abol-Enein et al [5] 2004 200 Distal aortic 50.6
Abdel-Latif et al [17] 2004 110 Distal common iliac 17.9
Herr et al [38] 2004 268 Variable 10.0
Herr et al [39] 2004 1,091 Variable 12.5
Fleischmann et al [40] 2005 101 Common iliac bifurcation 23.0
Honma et al [22] 2006 146 Common iliac bifurcation 13.9
Koppie et al [23] 2006 1,042 Variable 9.0
Kassouf et al [41] 2006 108 Aortic bifurcation 12.0
Stein et al [24] 2007 1,621 Inferior mesenteric  34.0
Steven and Poulsen [25] 2007 336 1-2 cm above aortic bifurcation 27.0
Dhar et al [26] 2008 322
336
Aortic bifurcation
Common iliac bifurcation
22.0
12.0
Kassouf et al [42] 2008 248 Aortic bifurcation 12.0
Wright et al [43] 2008 1,260 Not available 9.0
Wiesner et al [28] 2009 152 Below inferior epigastic 43.5
Osawa et al [29] 2009 60 Common iliac bifurcation 12.0
Jensen et al [30] 2009 170 Below inferior epigastic 25.4
Jeong et al [36] 2009 130 Variable 18.3
Dangle et al [34] 2010 120 Aortic bifurcation 36.9
portant factor determining the number of lymph nodes that 
can be removed during cystectomy. The extent of PLND 
and the number of retrieved nodes are summarized in 
Table 2 [3-5,7,10,12,17,22-26,28-30,34-43]. In two large 
cystectomy series that involved extended PLND, the me-
dian number of lymph nodes removed was 30 to 43 [4,37]. 
Poulsen et al reported that extending the boundaries of the 
PLND increased the mean number of retrieved lymph no-
des from 14 in a standard PLND to 25 when the dissection 
was extended to the bifurcation of the aorta [7].
　The number of lymph nodes that are assessed for pathol-
ogy also depends on several other factors, including the 
pathologist’s diligence in searching for and preparing the 
lymph nodes for histopathological evaluation and how the 
specimen is actually submitted for pathological evaluation. 
Simply converting from an en bloc technique to the sub-
mission of six separate lymph node packets increases the 
mean number of retrieved lymph nodes by more than 
three-fold [44]. In addition, individual variation between 
patients in terms of lymph node numbers may also affect 
the number of nodes that are retrieved.
LYMPH NODE STATUS AND PROGNOSIS
Lymph node status is known to be an important prognostic 
variable in bladder cancer. Patients with nodal metastases 
are at high risk of cancer recurrence and death from the 
disease. Therefore, adjuvant treatment with chemotherapy 
could benefit this patient population. However, although 
accurate determination of lymph node status is vital in de-
termining patient prognosis, it is unclear to what extent it 
should influence decision-making regarding adjuvant 
therapy.
1. Number of removed lymph nodes 
A Danish group was the first to assess how the extent of 
PLND influenced survival [7]. For this purpose, 194 consec-
utive patients treated by radical cystectomy were analyzed 
retrospectively. The authors reported that the 5-year re-
currence-free survival rate was 62% for the extended 
PLND group and 56% for the limited PLND group; this dif-
ference did not achieve statistical significance. However, 
a subgroup analysis of 117 patients with ≤pT3a primary 
tumors showed that extended and limited PLND were as-
sociated with survival rates of 85% and 64%, respectively; 
this difference was significant.
　Leissner et al reviewed their experience with 447 radical 
cystectomy cases [10]. The planned field of dissection was 
up to the aortic bifurcation and the mean number of re-
moved nodes was 14.7. They found that the number of re-
trieved nodes correlated with cancer-specific survival and 
that a significant survival advantage was noted when ≥16 Korean J Urol 2010;51:371-378
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nodes were removed: if more than 16 lymph nodes were re-
moved, the 5-year recurrence-free survival increased from 
63% to 85% in organ-confined tumors, from 40% to 55% in 
pT3 tumors, and from 25% to 53% in patients with up to 
five lymph node metastases. 
　Further support for a thorough PLND at cystectomy is 
demonstrated by the fact that even N0 patients demon-
strate improved survival if more nodes are removed, pre-
sumably because this eliminates micrometastatic disease 
[35]. Moreover, when Herr et al analyzed 667 patients un-
dergoing radical cystectomy, they found that the survival 
of both node-negative and node-positive patients was im-
proved and the local recurrence rate was reduced when 
more lymph nodes were removed [45]. 
　These data underscore the importance of a more ex-
tended PLND regardless of the presence of node meta-
stases. However, the reasons for the observations de-
scribed above are less clear. Some clinicians suggest that 
extended PLND has a potential therapeutic effect that is 
due to the surgical clearance of micrometastases. Equally 
if not more plausible explanations are that the retrieval of 
more lymph nodes improves the accuracy of staging, the 
guidance of downstream adjuvant therapies, and the dif-
ferential selection based on health status; however, these 
possibilities have been relatively discounted.
　These findings indicate that the higher lymph node 
counts obtained by an extended PLND are associated with 
improved survival. This observation, together with the fact 
that up to 25% of the patients who undergo radical cys-
tectomy have nodal metastases and 30% of patients with 
node-positive disease can be cured by surgery, suggests 
that thorough PLND is needed to completely remove the 
disease burden [13]. However, at present, there is still no 
widely held consensus regarding the limits or absolute 
boundaries of PLND or the minimum number of lymph no-
des that should be removed. 
2. Tumor burden
Several studies have demonstrated that greater numbers 
of cancer-containing nodes are associated with worse sur-
vival outcomes, which suggests that a higher number of 
positive nodes is indicative of a greater tumor burden. 
　When Smith and Whitmore analyzed 134 patients who 
were found after radical cystectomy to have lymph node 
metastases, they discovered that survival correlated di-
rectly with the number of metastatic lymph nodes [46]. 
This study was followed by several studies examining the 
prognostic impact of the tumor burden as defined by the 
number of positive nodes. This included the study by Herr 
and colleagues [45], who showed that the survival of pa-
tients with positive nodes who underwent radical cys-
tectomy was significantly better if ≤4 positive nodes were 
present than if there were ＞4 positive nodes (37% vs. 13%). 
In addition, they went on to show that when ＞11 nodes 
were resected, patients showed better survival and less re-
currence [45]. Similar observations were made by other 
groups. For example, Steven and Poulsen [25] found that 
overall survival was improved if 5 or fewer positive nodes 
were detected (50% vs. 13%). Mills et al also showed this 
[12], whereas Stein et al found that patients with ≤8 meta-
static nodes had significantly better 10-year recurrence- 
free survival rates than did those with ＞8 metastatic nodes 
(40% vs. 10%) [37]. Moreover, when the Mansoura group 
stratified positive nodes (1 vs. 2-5 vs. ＞5), this variable was 
statistically significant in both the univariate and the mul-
tivariate analyses [17]. This was also the case for a pop-
ulation-based study that used the SEER database (1 vs. 2 
vs. 3 vs. ＞3 positive nodes) [43]. 
　However, in the study by Kassouf et al, although the 
number of involved nodes was significantly associated with 
recurrence-free survival in the univariate analysis, this 
variable lost statistical significance in the multivariate 
analysis [41]. 
3. The concept of lymph node density 
In 2003, Herr introduced the concept of ratio-based lymph 
node staging for bladder cancer, in which the ratio is the 
number of positive nodes divided by the total number of re-
trieved nodes [35]. This lymph node density concept was 
an attempt to standardize lymph node staging, which had 
been complicated by variability in the extent of PLND, the 
meticulousness with which the pathologist identified and 
reported nodal counts, and the innate anatomy of in-
dividual patients. By standardizing lymph node staging in 
this manner, patients could be stratified according to 
node-positivity and adjuvant therapies, and clinical trials 
could be applied more uniformly. Although various lymph 
node density cutoff values have been reported in the liter-
ature, the most commonly used lymph node cutoff is 20%. 
Almost all studies performed on this issue have confirmed 
the independent prognostic significance of lymph node 
density upon multivariate analysis [17,22,25,28,29,31,35- 
37,40-43,47]. These data are summarized in Table 3.
　Because the tumor-node-metastasis (TNM) classification 
does not account for the surgeon’s ability to remove the af-
fected nodal tissue, it may underestimate the extent of re-
gional nodal involvement. Herr et al reported that in a mul-
tivariate analysis, lymph node density stratified patients 
according to disease-specific survival better than did either 
the conventional staging system or the absolute number of 
positive lymph nodes [45]. Similarly, Kassouf et al found 
that, of the variables tested, only a lymph node density 
greater than 20% was significantly predictive of a de-
creased disease-specific survival [42]. In contrast, Fleisch-
mann et al reported that when multivariate analysis was 
performed by use of primary tumor stage, the number of 
positive lymph nodes, lymph node density, and extra-
capsular nodal extension, only extracapsular nodal ex-
tension retained statistical significance [40]. 
　Several studies have compared the absolute number of 
positive nodes with lymph node density in terms of their 
ability to predict disease-specific survival. Stein et al re-
ported that on multivariate analysis, the number of lymph 
nodes involved (＞8 vs. ≤8) performed better than did lymph Korean J Urol 2010;51:371-378
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TABLE 3. Survival rates according to lymph node density
References Year No. of patients Cut-off (%) 5-year RFS 5-year DSS 5-year OS
Her [35] 2003 162 ＜20
＞20
-
-
64.0%
  8.0%
-
-
Stein et al [37] 2003 244 ＜20
＞20
44.0%
17.0%
-
-
43.0%
8.0%
Konety et al [47] 2003 361 1-25
26-50
51-75
76-100
-
-
-
-
HR 1.00
HR 0.89
HR 1.55
HR 1.72
-
-
-
-
Abdel-Latif et al [17] 2004 110 ＜10
10-20
＞20
56.2%
38.9%
16.4%
-
-
-
-
-
-
Fleischmann et al [40] 2005 101 ＜20
＞20
41.0%
15.0%
-
-
40.0%
15.0%
Honma et al [22] 2006 25 ＜20
＞20
-
-
58.0%
15.0%
-
-
Kassouf et al [41] 2006 108 ＜25
＞25
38.1%
10.6%
-
-
37.3%
18.7%
Steven and Poulsen [25] 2007 64 ＜20
＞20
47.0%
25.0%
-
-
-
-
Kassouf et al [42] 2008 248 ＜20
＞20
-
-
54.6%
15.3%
-
-
Wright et al [43] 2008 1,260 ＜12.5
12.6-25
25.1-50
＞50
-
-
-
-
HR 1.00
HR 1.24
HR 1.62
HR 2.47
HR 1.00
HR 1.31
HR 1.54
HR 2.40
Wiesner et al [28] 2009 46 ＜11
＞11
-
-
38.0%
7.0%
-
-
Osawa et al [29] 2009 60 ＜25
＞25
-
-
-
-
39.6%
10.3%
Bruins et al [31] 2009 181 ＜4
＞4
52.0%
29.0%
-
-
46.0%
28.0%
Jeong et al [36] 2009 130 ＜18
＞18
-
-
HR 1.00
HR 2.77
-
-
RFS: recurrence-free survival, DSS: disease-specific survival, OS: overall survival, HR: hazard ratio
node density (＞20 vs. ≤20%) in predicting recurrence-free 
survival, though both factors remained statistically sig-
nificant [37]. Similarly, Abdel-Latif et al demonstrated 
that whereas both the number of positive nodes (1 vs. 2-5 
vs. ＞5) and the lymph node density (＜10 vs. 10-20 vs. ＞
20%) were statistically significant in univariate analyses, 
only the number of positive nodes remained significant in 
multivariate modeling [17]. In contrast, Kassouf et al re-
ported that whereas lymph node density (＞25 vs. ＜25%) 
remained significantly associated with overall and re-
currence-free survival in a multivariate model, the number 
of positive nodes lost statistical significance [41]. With re-
gard to population-based studies, Konety et al reported 
that whereas the number of positive nodes did not correlate 
significantly with survival, the lymph node density showed 
some predictive ability, especially at a cutoff of 50% [47]. 
However, Wright et al found that the number of positive 
nodes (1 vs. 2 vs. 3 vs. ＞3) and lymph node density (divided 
into quartiles) both correlated significantly with disease- 
specific and overall survival [43].
　Thus, lymph node density may be an attractive alter-
native to lymph node staging. However, because all lymph 
node density studies performed to date are retrospective, 
it remains unclear whether lymph node density improves 
prognostication relative to the standard nodal staging sys-
tem or the absolute number of positive nodes.
4. New parameters
The current TNM system is based on the number of positive 
lymph nodes and the size of the largest positive lymph node. 
Recently, a new concept in bladder oncology, namely, the 
aggregate size of all lymph node metastases, was investi-
gated. Stephenson et al reported that, after adjusting for 
pathologic T stage, lymphovascular invasion, lymph node 
density, comorbidity, and extranodal extension, the ag-
gregate lymph node metastasis diameter was a significant 
predictor of recurrence-free survival and overall survival 
[32]. However, important limitations of this study were 
that few patients underwent an extended PLND and the 
analysis was retrospective. Korean J Urol 2010;51:371-378
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MORBIDITY ASSOCIATED WITH PELVIC LYMPH 
NODE DISSECTION
A retrospective analysis did not detect a difference between 
limited and extended PLND groups in terms of mortality; 
moreover, the lymphocele formation rate was similar for 
these two groups (1.5% and 1.6%, respectively) [7]. Simi-
larly, another study showed that lymphoceles and lym-
phoedema occurred in 2% and 1% of patients who had ＜16 
and ≥16 lymph nodes removed, respectively [10]. More-
over, perioperative deaths or early complications that re-
lated directly to the PLND were not observed in 1,054 pa-
tients who all underwent an extended PLND [13]. These 
findings were confirmed recently by a study that ques-
tioned whether an extended PLND would increase morbid-
ity in patients who underwent radical cystectomy [48]. 
Although the extended PLND increased the operative du-
ration by 63 min, the limited and extended PLND groups 
did not differ significantly in terms of perioperative mortal-
ity, early complications, or the need for blood transfusions. 
Similarly, when a multicentre study prospectively eval-
uated the role of an extended PLND in 290 patients under-
going cystectomy for bladder cancer, none of the participat-
ing centers reported any significant adverse effects that 
were related to the extended PLND [4]. These findings sug-
gest that despite prolonging the operation, an extended 
PLND does not increase the complication rate either dur-
ing or after surgery. Indeed, it appears that the morbidity 
associated with an extended PLND is low and comparable 
to that associated with a more limited PLND.
　It should be noted that although the administration of 
neoadjuvant radiation or chemotherapy before cystectomy 
does not increase the morbidity and mortality associated 
with cystectomy, patients who have received these treat-
ments should be judged carefully with regard to also under-
going extended PLND [49]. This is because patients who 
have had higher doses of radiation therapy (＞60 Gy) are 
at greater risk of vascular and associated injuries when un-
dergoing a cystectomy [50].
CONCLUSIONS
A recent SEER analysis of 3,603 cystectomies that were 
performed between 1992 and 2003 revealed that PLND did 
not seem to be performed routinely during this period; 
moreover, when it was performed, the number of nodes re-
trieved was suboptimal [51]. However, a more recent SEER 
analysis showed that there has been an improvement over 
time in terms of the performance of PLND and the node 
counts obtained during radical cystectomy [52]. 
　Lymph node assessment is an important component of 
bladder cancer staging because nodal status correlates 
strongly with prognosis. PLND also contributes to the cure 
of some patients with nodal metastases. Lymph node den-
sity may become a more useful prognostic variable in pa-
tients with high-risk node-positive disease. 
　Although the optimal extent of PLND remains to be de-
fined and cannot be determined on the basis of the retro-
spective studies that have been published to date, current 
observations suggest that an extended PLND not only pro-
vides prognostic information, it also has a clinically sig-
nificant therapeutic benefit for patients with invasive 
bladder cancer. However, whether extended PLND im-
proves overall survival or whether that benefit applies only 
to particular subgroups should be addressed by random-
ized clinical trials. Such future studies will help to identify 
the optimal staging template and to clarify the therapeutic 
benefits of PLND.
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